CSPC Pharmaceutical Group Ltd.

BOSTON, MA, USA I March 31, 2025 I Radiance Biopharma, Inc. (“Radiance” or the “Company”), a clinical stage biopharmaceutical company advancing Antibody Drug Conjugates (‘ADCs’), today announced that the U.S. Food and Drug Administration (“FDA”) has cleared its Investigational New Drug (“IND”) application for RB-164™, an ROR-1 targeted ADC for hematologic and solid malignancies. The IND supports the initiation of a Phase 1 dose escalation and expansion clinical trial of RB-164™ in patients with ROR-1 positive hematologic and solid cancers in the United States of America. “The FDA’s clearance of the IND application allows us the opportunity to proceed with the Phase 1 Clinical Trial with a potentially best-in-class ROR-1 targeted ADC for patients with hematologic and solid tumors,” said Marc Lippman, MD, Chairman of Radiance. “Radiance marks the clearance by the FDA of the IND application for RB-164™ to be a significant milestone for the Company, with its first clinical-stage product candidate to advance into clinic for treating unmet needs in major cancer indications,” said Robert Brooks, JD, Chief Executive Officer. The Phase 1 clinical trial is expected to be an open-label, dose escalation and expansion study to evaluate the safety and efficacy of RB-164™ in subjects with ROR-1 positive hematologic cancers such as lymphoma, and various solid tumors. The dose escalation and dose expansion portions of the trial are expected to evaluate safety, tolerability, and pharmacokinetics as well as anti-tumor activity defined by overall response rate, duration of response, and disease control rate. About RB-164™ RB-164™ is a next generation ADC that targets ROR-1 expression with an Fc-silenced monoclonal antibody, glutamine side chain-based conjugation to prevent retro-Michael elimination, and site specific conjugation to deliver a homogeneous Drug-to-Antibody distribution for an improved pharmacokinetic and toxicology profile, to the payload MMAE. An IND application for RB-164™ (SYS6005) has been cleared by China’s regulatory agency, the National Medical Products Administration (NMPA). It is currently being investigated by CSPC Megalith Biopharmaceutical Co., Ltd, a subsidiary of CSPC Pharmaceutical Group Limited (CSPC; HKEX: 01093), in a Phase I Clinical Trial in China in hematologic and solid tumors. Radiance has an Exclusive License with CSPC and plans to collaborate to execute clinical development of the drug. Radiance will be responsible for the clinical development of RB-164™ in its licensed territories – the United States, Canada, United Kingdom, western Europe, and Australia. About Radiance Radiance is focused on developing a pipeline of antibody-based cancer therapeutics including monospecific and bispecific Antibody Drug Conjugates for the treatment of cancer and other unmet medical needs. In addition to RB-164™, Radiance is developing RB-201™, a HER2/TROP2 Bispecific ADC in preclinic stages. For more information on Radiance visit www.radiancebiopharma.com. SOURCE: Radiance

Our analysis of February data reveals key trends in global preclinical-stage biopharmaceutical financing. For contextual understanding, we recommend beginning with the following article. Highlights of Financing and Strategic Collaborations in the Preclinical Biopharmaceutical Sector: February 2025(1) 12.Harbour BioMed and Insilico Medicine Form Strategic Partnership to Advance AI-Driven Antibody Discovery and Development Harbour BioMed and Insilico Medicine have established a strategic partnership aimed at accelerating the development of therapeutic antibodies by integrating artificial intelligence (AI) with antibody research. This collaboration seeks to leverage AI’s potential in antibody applications and target-specific research, aiming for breakthrough advancements in biopharmaceutical innovation. The partnership not only underscores AI’s growing importance in drug discovery but also highlights the transformative power of cross-industry collaboration in driving innovation. According to the agreement, both companies will combine Harbour BioMed’s expertise in antibody development with Insilico Medicine’s AI-driven drug discovery platform. Notably, Insilico Medicine’s Integrated Drug Creation™ platform, which utilizes generative AI and a scalable wet lab system, can significantly reduce the time from data collection to molecular design and experimental validation to approximately six weeks. This highly efficient research process dramatically accelerates drug discovery and facilitates rapid clinical trial progression for promising drug candidates. The initial phase of the collaboration will focus on specific disease targets, although financial terms and drug details have not been disclosed. However, given that similar partnerships in the industry often involve multimillion or even billion-dollar deals, both companies are expected to make substantial investments to ensure the project’s success. Additionally, Insilico Medicine has already achieved significant milestones in collaborations with major pharmaceutical companies, such as AstraZeneca, which suggests that its partnership with Harbour BioMed could generate substantial economic and social value. As AI continues to reshape the healthcare industry, more pharmaceutical companies are exploring ways to integrate AI into their R&D pipelines. The Harbour BioMed-Insilico Medicine collaboration exemplifies this trend, demonstrating how AI-driven solutions can enhance global competitiveness and set a benchmark for industry innovation. Looking ahead, similar cross-sector collaborations are expected to emerge, further propelling advancements in biopharmaceutical research. Despite its immense potential, AI-driven drug discovery still faces challenges, including data privacy concerns, algorithmic transparency issues, and regulatory uncertainties. While AI accelerates research efficiency, stakeholders must work collectively to address these challenges. Through continuous technological innovation and the establishment of robust regulatory frameworks, AI is poised to play an increasingly pivotal role in future drug discovery and development, ultimately providing more effective treatment options for patients worldwide. 13. Epitopea Partners with MSD to Develop RNA-Based Cancer Immunotherapies On February 19, 2025, transatlantic cancer immunotherapy company Epitopea announced a licensing and research collaboration agreement with Merck & Co. (MSD) to identify Cryptigen™ tumor-specific antigens (TSAs) in an undisclosed solid tumor type. These antigens originate from non-coding regions previously considered "junk DNA" and exhibit shared, non-mutated, and aberrant expression across multiple patients. Through this collaboration, the two companies aim to leverage Epitopea's proprietary CryptoMap™ platform to discover novel immunogenic Cryptigen™ TSAs and develop off-the-shelf RNA-based immunotherapies for various refractory cancers. Under the terms of the agreement, Epitopea will use its CryptoMap™ platform to identify and provide novel Cryptigen™ TSAs for predefined tumor types. MSD will have exclusive rights to develop and commercialize any therapeutic products resulting from the collaboration. In return, Epitopea will receive an undisclosed upfront payment and be eligible for milestone payments of up to $300 million per product. This financial arrangement not only highlights MSD’s commitment to the project but also underscores the immense potential of Epitopea’s technology platform. At the core of Epitopea’s technology is its CryptoMap™ platform, which integrates immunopeptidomics, genomics, and bioinformatics pipelines to identify aberrantly expressed tumor-specific antigens hidden within cancer "junk" DNA. This innovative approach opens new avenues for developing highly effective immunotherapies targeting specific tumor types. Furthermore, since these antigens are commonly present across multiple patients, therapies based on them can be applied to a broader patient population, enhancing accessibility and efficacy. This collaboration not only validates Epitopea’s technological capabilities but also positively impacts the entire cancer immunotherapy field. As more partnerships of this kind emerge, the number of therapies targeting newly discovered tumor-specific antigens is expected to grow significantly in the coming years. For MSD, this collaboration strengthens its leadership in immuno-oncology and could yield a series of breakthrough therapies. At the same time, it marks a step forward in the transition from traditional chemotherapy to more personalized and precise cancer treatments. Since its founding, Epitopea has garnered support from top life sciences investors, including Advent Life Sciences, CTI Life Sciences, and Cambridge Innovation Capital. To date, the company has raised over $45 million, providing a strong financial foundation for its R&D activities. Epitopea plans to accelerate the development of its preclinical pipeline as it moves toward becoming a clinical-stage company. With the deepening collaboration with MSD, Epitopea is poised to introduce a range of innovative cancer immunotherapies in the coming years, offering hope to cancer patients worldwide. 14. Polymed Partners with Photys Therapeutics for Global Development of HPB-143 On February 18, 2025, Polymed announced a major partnership with Photys Therapeutics, granting Photys the rights to develop, manufacture, and commercialize the IRAK4-targeting protein degrader HPB-143 in all global markets except Greater China and Southeast Asia. In return, Polymed will receive multiple forms of compensation, including upfront and near-term payments, clinical development milestone payments, and sales royalties, while also holding an equity stake in Photys. This collaboration aims to accelerate the development of HPB-143 and expand its global market presence. Compared to the IRAK4-targeting protein degrader KT-474, which is currently in Phase II clinical trials internationally, Polymed’s HPB-143 has demonstrated superior oral bioavailability, reaching 49% in mouse studies. Additionally, it exhibits weaker inhibition of the cardiac ion channel hERG, suggesting improved cardiovascular safety in humans. In multiple mouse disease models, HPB-143 has shown lower effective doses and superior efficacy. As a PROTAC (Proteolysis-Targeting Chimera), HPB-143 specifically degrades the IRAK4 protein by hijacking the intracellular ubiquitin-proteasome system, effectively modulating key signaling pathways involved in inflammatory responses and tumor progression. IRAK4 plays a crucial role in human inflammatory responses and tumorigenesis, making it a highly promising target for protein degraders in treating autoimmune diseases such as atopic dermatitis and hidradenitis suppurativa. The therapeutic demand for these conditions remains largely unmet, with existing treatments often limited by efficacy or side effects. With its unique mechanism of action and superior pharmacological profile, HPB-143 has the potential to provide a safer and more effective treatment option for patients. HPB-143 has already secured approval from both the U.S. FDA and China's National Medical Products Administration (NMPA) to conduct clinical trials. According to Photys Therapeutics' plan, a Phase I clinical study for HPB-143 is set to launch this year, marking a critical step in evaluating the drug's safety, tolerability, and preliminary efficacy. As clinical trials progress, HPB-143 has the potential to become one of the first-in-class IRAK4 degraders to reach the market, offering new hope for patients with autoimmune diseases worldwide. This partnership not only reflects the global recognition of Polymed’s PROTAC drug development platform but also signifies the commitment of both companies to advancing HPB-143’s development through resource integration. Photys Therapeutics, leveraging its proprietary PHICS™ technology and other proximity-based modalities, is dedicated to developing a pipeline of therapies targeting cancer, autoimmune diseases, and cardiometabolic disorders. Through this collaboration, both companies have the opportunity to expand their product portfolios and achieve multiple key development milestones in the coming years. For the broader pharmaceutical industry, this partnership serves as a positive signal of the potential of innovative therapies in addressing unmet medical needs. 15. Perceive Pharma Secures $15 Million Series A Funding to Advance Ophthalmic Neuroprotective Therapy On February 18, 2025, Perceive Pharma, a company focused on developing novel small-molecule ophthalmic therapeutics, announced the completion of a $15 million Series A funding round. The financing was backed by several renowned investment firms, including Deerfield Management, Johnson & Johnson Innovation – JJDC, Inc., Braidwell LP, GV, Retinal Degeneration Fund, and Catalio Capital Management, LP. The funds will be used to advance its glaucoma program to the clinical readiness stage and further expand its research pipeline. One of Perceive Pharma’s core products is PBI-671, a first-in-class drug candidate designed to prevent vision loss caused by glaucoma. All currently approved glaucoma treatments focus on reducing intraocular pressure (IOP), yet approximately half of glaucoma patients continue to experience vision loss despite having normal IOP. PBI-671 is based on a neuroprotective pathway first identified through genomic screening and aims to directly protect retinal cells, offering a potential treatment for patients whose disease continues to progress despite existing therapies. Perceive Pharma's research and development efforts are built on a strong scientific foundation, providing the company with a unique advantage in identifying new therapeutic targets and developing transformative vision-protection therapies. With the successful completion of its Series A financing, the company will accelerate the advancement of its lead therapy to address the medical needs of more than 1.5 million patients worldwide suffering from progressive glaucoma. Additionally, Perceive Pharma plans to explore treatment opportunities for other undisclosed diseases. Notably, Perceive Pharma is part of JLABS @ San Diego, a division of Johnson & Johnson Innovation – JLABS, a global life sciences incubator network. Through this platform, startups gain access to cost-efficient laboratory space, equipment resources, and expert support, helping to accelerate the development of innovative products. Such support is crucial for emerging companies like Perceive Pharma as they navigate critical growth and development stages. 16. Lexenpharm and Sun-Novo Pharmaceutical Join Forces to Revolutionize Asthma and COPD Treatment Recently, Lexenpharm and Sun-Novo Pharmaceutical announced a regional strategic partnership for the development of two innovative drug projects, LXP2311 and LXP0531, in mainland China. Through this collaboration, both companies will leverage their technological expertise to advance the research, development, and commercialization of these breakthrough therapies, bringing new hope to the medical industry. Current COPD treatments primarily rely on short-acting or long-acting monotherapies, which often have limited efficacy and duration of action. To address this challenge, Lexenpharm and Sun-Novo have jointly developed LXP2311 and LXP0531, the world's first ultra-long-acting combination inhalation formulations. In particular, LXP2311, the first ultra-long-acting LABA/LAMA combination therapy, requires only once-daily administration and can be delivered via a standard jet nebulizer, significantly enhancing patient convenience. Meanwhile, LXP0531 is the first ultra-long-acting ICS/LABA combination therapy, recommended for the treatment of asthma and COPD, offering improved ease of use for both physicians and patients. The success of the LXP2311 and LXP0531 projects is supported by five core technologies, including nebulized inhalation formulation and soft mist inhalation technology. These advancements not only enhance drug efficacy and safety but also significantly improve the patient experience. For instance, the application of nano-scale sterile suspension technology and Blow-Fill-Seal (BFS) aseptic technology ensures efficient drug delivery and stability within the body, providing better disease control. These technological innovations are expected to have a substantial impact on improving treatment outcomes for asthma and COPD patients worldwide. Asthma and COPD remain major global public health concerns, with COPD ranking as the second leading disease in China and the third leading cause of death worldwide. It is estimated that COPD results in an annual global economic burden exceeding $4.3 trillion, with China alone bearing a financial burden of $1.36 trillion. Given the severity of this situation, the development of more effective and convenient treatment options is an urgent necessity. The partnership between Lexenpharm and Sun-Novo reflects their commitment to addressing this critical need by providing better therapeutic solutions for patients. 17.DAAN Biotherapeutics and LigaChem Biosciences Enter Exclusive Antibody Licensing Agreement to Advance ADC Therapy Development February 13, 2025, Seoul, South Korea – DAAN Biotherapeutics, a leading innovative drug development company specializing in T-cell receptor (TCR)-based therapies, has announced an exclusive licensing agreement with LigaChem Biosciences. This collaboration aims to develop a novel tumor-targeting antibody to facilitate the advancement and commercialization of antibody-drug conjugates (ADCs). By leveraging their respective technological strengths, the two companies will work together to drive progress in ADC therapies for solid tumor patients. With its cutting-edge next-generation antibody technology, superior target discovery, and antibody development capabilities, DAAN Biotherapeutics has successfully built a proprietary pipeline focused on developing antibodies targeting tumor markers overexpressed in solid cancers. This achievement is supported by its strategic partnership with OmniAb. Additionally, DAAN has developed a platform called TACTIC (Tumor-Activated Conditional T-cell Connector), designed to be a global leader in solid tumor-targeted T-cell activators. These technological advancements provide a strong foundation for the development of ADC therapies. The collaboration between DAAN Biotherapeutics and LigaChem Biosciences represents an effective integration of their technologies and resources, marking a significant milestone in the field of solid tumor treatment. It is expected to accelerate the development of novel ADC therapies and provide patients with more effective treatment options. As the partnership deepens, more research findings are anticipated to translate into practical applications, contributing to the fight against cancer. Looking ahead, DAAN Biotherapeutics plans to continue expanding its collaborations with global pharmaceutical companies, particularly in the ADC sector. Furthermore, the company aims to achieve breakthroughs in T-cell therapies, especially through the development of novel T-cell connectors using its TACTIC platform. Through continuous exploration and innovation, DAAN Biotherapeutics is steadily advancing toward its goal of becoming a global leader in cancer treatment. 18.Xilio Therapeutics Announces Multiple Masked T-cell Engager Programs and Collaboration Agreement with AbbVie February 12, 2025 – Xilio Therapeutics, Inc., a clinical-stage biotechnology company focused on discovering and developing tumor-activated immunotherapies, has announced three wholly-owned preclinical programs targeting prostate-specific membrane antigen (PSMA), claudin 18.2 (CLDN18.2), and six-transmembrane epithelial antigen of the prostate 1 (STEAP1) with masked T-cell engagers. Additionally, Xilio has entered into a collaboration, licensing, and option agreement with AbbVie to leverage Xilio’s proprietary tumor-activated technology platform to develop novel tumor-activated immunotherapies. T-cell engagers are designed to direct immune effector cells against cancer cells by simultaneously binding tumor-associated antigens expressed on the surface of cancer cells and the T-cell receptor complex on T cells, thereby inducing T-cell-mediated tumor cell killing. However, despite their significant therapeutic potential in various advanced solid tumors, the widespread application of T-cell engagers has been limited by toxicity concerns. Xilio is utilizing its clinically validated tumor-activated platform to advance a series of novel masked T-cell engagers with conditionally regulated half-life properties, aiming to achieve potent, localized T-cell activation and tumor cell destruction while improving the therapeutic index. Xilio is currently progressing three wholly-owned preclinical programs, each targeting a distinct tumor-associated antigen: ·PSMA – a promising T-cell engager target for prostate cancer ·CLDN18.2 – a potential T-cell engager target for gastric, pancreatic, esophageal, and lung cancers ·STEAP1 – a viable target for prostate, colorectal, and lung cancers Xilio expects to nominate development candidates and submit Investigational New Drug (IND) applications for these programs in the coming years. Under the terms of the collaboration agreement with AbbVie, Xilio will receive a total upfront payment of $52 million, including $42 million in cash and $10 million in Xilio common stock purchased by AbbVie at a premium. Xilio has granted AbbVie an exclusive option to initiate an initial program for the discovery and development of masked T-cell engagers, with the potential for two additional programs to be launched under the agreement. Moreover, Xilio will be eligible for up to $2.1 billion in additional milestone payments, including option fees, as well as development, regulatory, and commercial sales milestones. Based on its current operational plans, Xilio expects its existing cash and equivalents, combined with the upfront payment from the AbbVie agreement, to fund its operating and capital expenditure needs until the first quarter of 2026. Xilio will hold an investor conference call and webcast on February 12, 2025, to provide further details on this announcement and invite investor participation. These strategic moves not only strengthen Xilio’s financial position but also ensure continued investment in future research and development. 19.Ellipses Pharma Acquires First-in-Class Next-Generation Immuno-Oncology Drug GENA-104 to Accelerate Cancer Treatment Development Ellipses Pharma Limited (Ellipses), a global drug development company dedicated to accelerating cancer treatment through innovative drug development models, announced on February 11, 2025, that it will develop a next-generation immuno-oncology drug aimed at addressing the needs of cancer patients who do not respond to existing checkpoint inhibitors. Ellipses has secured the global rights to ‘GENA-104,’ a first-in-class immuno-oncology monoclonal antibody targeting CNTN4, a recently identified checkpoint protein highly expressed across multiple tumor types. GENA-104 was originally discovered by the South Korea-based biotechnology company Genome & Company (Genome), which specializes in the development of novel cancer-targeting antibodies and antibody-drug conjugates (ADCs). Under the agreement with Genome, Ellipses will assume full responsibility for the future clinical development of GENA-104, designating it as EP0089. The potential of EP0089 as a novel immuno-oncology therapy was highlighted in a landmark study published in Science Immunology in October 2024. The Phase I IND application for EP0089 was approved by the South Korean Ministry of Food and Drug Safety in January 2024. Ellipses plans to initiate Phase I clinical trials in South Korea in 2025 and subsequently expand to the United States and Europe upon obtaining the necessary regulatory approvals. This new therapeutic approach aims to inhibit the CNTN4-APP checkpoint interaction on T cells, thereby enhancing tumor cell destruction, making it particularly promising for cancers resistant to traditional checkpoint inhibitors. This collaboration marks a significant milestone for Ellipses Pharma in expanding its pipeline and represents a crucial advancement in cancer treatment. By acquiring breakthrough candidates such as EP0089, Ellipses reaffirms its commitment to rapidly identifying and developing top-tier therapies to provide new treatment options for patients as quickly as possible. As further research data emerges and clinical trials progress, EP0089 has the potential to transform the treatment landscape for certain refractory cancers, offering new hope to patients worldwide. 20.Alloy Therapeutics Partners with Pfizer to Develop a New Antibody Discovery Platform Boston, February 11, 2025 – Alloy Therapeutics Inc. (Alloy), a biotechnology ecosystem company committed to democratizing access to cutting-edge drug discovery technologies, has announced its latest strategic collaboration with Pfizer. This partnership aims to develop a novel platform designed to enhance Pfizer’s ability to discover highly specific and effective antibodies for challenging targets that current antibody discovery technologies struggle to address. Under the terms of the agreement, Alloy will receive an upfront payment from Pfizer and will be eligible for pre-specified preclinical-to-commercial milestone payments related to products developed using the new platform. Alloy’s ATX-Gx platform has rapidly become the industry standard for fully humanized transgenic mice, utilized by over 170 partners to advance various therapeutic discovery programs. Alloy remains committed to reinvesting its revenue into innovation and has continuously expanded its murine platform by incorporating ATX-GL™, which features a complete human lambda library, and ATX-GKH™, an ultra-immune strain designed to enhance antigen-specific B-cell production and improve IgG class switching. In addition to this collaboration, Alloy and Pfizer have worked together on multiple antibody discovery initiatives, including the use of Alloy’s ATX-CLC platform. This platform enables the expression of common light-chain antibodies with full heavy-chain diversity, facilitating the efficient and modular discovery of bispecific antibodies. 21.Bolt Biotherapeutics and Toray Collaborate on a Novel ISAC Therapy Targeting Caprin-1 On February 11, 2025, Bolt Biotherapeutics announced a global collaboration with Toray Industries to co-develop a therapeutic targeting Caprin-1, a novel cancer target discovered by Toray. The two companies are working together to develop a Boltbody™ immune-stimulating antibody-drug conjugate (ISAC) targeting Caprin-1, intended for use in multiple solid tumor types. Under the existing joint development and licensing agreement, Toray is providing its proprietary Caprin-1-targeting antibody, TRK-950, while Bolt contributes its proprietary linker-payload technology from the Boltbody™ ISAC platform. Caprin-1 is a tumor-specific antigen that is highly expressed on the cell membrane of most solid tumors while exhibiting minimal expression in normal tissues. Additionally, Caprin-1 has been shown to promote tumor growth and metastasis. Toray’s asset, TRK-950, is a monoclonal antibody targeting Caprin-1 and is currently in Phase II development for gastric cancer, validating the antigen’s potential as an ISAC target. TRK-950 functions by binding to and attacking cancer cells expressing Caprin-1, with particularly strong expression observed in gastric cancer and other solid tumors, as well as in metastatic cancer cells and cancer stem cells. Bolt’s Boltbody™ ISAC platform combines the precision of antibodies with the strength of both innate and adaptive immune systems to reprogram the tumor microenvironment and generate potent anti-cancer responses. Each Boltbody™ ISAC candidate comprises a tumor-targeting antibody, a non-cleavable linker, and a proprietary immune-stimulatory payload. This combination activates myeloid cells, initiating a positive feedback loop that releases cytokines and chemokines, attracts additional immune cells, lowers the activation threshold of immune responses, and enhances the number of activated immune system cells in the tumor microenvironment, ultimately promoting a robust immune response. In recent years, Toray has increasingly focused on "Life Innovation," accelerating advancements in medical technology and disease prevention with the goal of alleviating the burden on healthcare professionals and helping people live longer, healthier lives. Oncology has been identified as a key area of focus, and Toray is committed to developing industry-leading therapeutic approaches with the potential to significantly improve patient outcomes. The collaboration with Bolt is part of Toray’s broader mission to create a healthier society through the development of innovative medicines, reflecting the shared commitment of both companies to providing better treatment options for cancer patients across various indications. This partnership builds upon the highly productive interactions between Alloy and Pfizer, further solidifying the companies’ collaboration in antibody discovery and technological innovation. Through joint efforts, the two parties aim to drive scientific progress and accelerate the development of new therapies, ultimately benefiting patients. As the collaboration advances, it is expected to yield additional breakthrough innovations that will contribute to the global healthcare landscape. 22.XtalPi Holdings and Probable Biotechnology Join Forces to Accelerate First-in-Class Drug Discovery On February 10, 2025, XtalPi Holdings announced the completion of a strategic investment in Probable Biotechnology and the establishment of an in-depth research and development collaboration. Together, the two companies will advance the discovery and development of First-in-Class (FIC) drugs targeting novel mechanisms identified by Probable Biotechnology to address significant unmet clinical needs. This partnership aims to leverage XtalPi’s cutting-edge AI and robotics-driven platform alongside Probable Biotechnology’s pioneering research in translational regulation to accelerate drug development. Probable Biotechnology specializes in modulating cellular states through ribosome and kinase methylation switches, developing small-molecule targeted therapies for major diseases such as cancer and inflammation. XtalPi, known for its industry-leading AI and robotics-powered drug discovery platform, integrates high-precision quantum physics-based computational chemistry algorithms with over 300 AI models. This platform enables efficient exploration of large-scale chemical space to design and optimize molecules with both innovation and strong drug-like properties. By partnering with XtalPi, Probable Biotechnology will gain access to powerful computational and experimental tools, significantly enhancing the speed and success rate of its FIC drug development efforts. The first project under this collaboration focuses on small-molecule inhibitors targeting the RAS-MAPK signaling pathway, particularly for pan-cancer indications associated with RAS mutations. These inhibitors have demonstrated the ability to overcome resistance to KRAS-targeted therapies in resistant mouse models. When used in combination with existing standard-of-care therapies, they have shown significant advantages in tumor growth inhibition, prolonged survival, and reduced mortality in preclinical studies. Additionally, Probable Biotechnology is developing a novel small-molecule inhibitor for the treatment of acute pancreatitis. Preclinical data indicate promising pharmacokinetic properties, efficacy, and a favorable safety profile, offering a potential new therapeutic option for patients. By combining Probable Biotechnology’s expertise in translational regulation with XtalPi’s AI-driven drug discovery capabilities, this partnership aims to push the boundaries of innovation in drug development. Through this collaboration, the two companies seek to accelerate the discovery of transformative therapies, bringing hope to patients suffering from challenging diseases worldwide. 23.LEO Pharma and DEBRA Research Collaborate to Advance Treatment for Epidermolysis Bullosa LEO Pharma and DEBRA Research announced a partnership aimed at accelerating the development of treatments for epidermolysis bullosa (EB). This rare genetic disorder causes extremely fragile skin that can blister and develop wounds from minor friction or trauma. The collaboration will not only enhance understanding of EB's pathological mechanisms but also develop new therapeutic strategies to improve patients' quality of life. Epidermolysis bullosa is a group of heterogeneous genetic disorders characterized by mutations in structural skin proteins that lead to varying degrees of skin and mucosal fragility. Current treatments primarily focus on wound care, pain management, and infection prevention, lacking fundamental therapies targeting the underlying cause. For certain severe types of EB, such as dystrophic EB, existing treatments often fail to effectively control symptoms, creating an urgent need for innovative therapeutic approaches. The collaboration between LEO Pharma and DEBRA Research will focus on basic research and clinical trials, exploring various novel therapies including gene therapy. For example, the topical gene therapy B-VEC has shown significant efficacy in promoting wound healing in dystrophic EB patients during Phase 3 clinical trials. Additionally, researchers are investigating other cell-based therapies such as bone marrow transplantation and protein replacement therapy. Through this partnership, both parties hope to discover more effective treatments and accelerate their translation into clinical applications. While the specific financial terms of the collaboration remain undisclosed, it is anticipated that LEO Pharma, as an international pharmaceutical company specializing in dermatology, will provide substantial funding and technical resources for the project. This will help accelerate the translation from laboratory to market, enabling new therapies to benefit patients more quickly. Meanwhile, DEBRA Research, as an organization long committed to EB research and patient support, will contribute its disease-specific expertise and network resources. As the collaboration between LEO Pharma and DEBRA Research deepens, it is expected to yield a series of breakthrough research outcomes in the near future. Beyond directly improving the health of EB patients, this partnership will also enhance the medical community's understanding of genetic skin disorders. More importantly, it demonstrates the tremendous potential of cross-institutional collaboration in addressing rare diseases, providing a replicable model for treating other similar conditions. Ultimately, such collaborations may alleviate the socioeconomic burden on EB patients and their families while improving their quality of life. Summary Looking back at February 2025, we can observe several notable characteristics and trends in financing, collaborations, and licensing activities in the preclinical drug sector. First, capital market enthusiasm has not waned; rather, driven by both policy support and technological advancements, investment in the biopharmaceutical industry has continued to grow. According to statistics, by the end of February, the global biopharmaceutical sector had completed financing activities totaling over $3.2 billion, providing crucial funding support to numerous early-stage R&D companies and helping them bridge the gap from laboratory to market. Second, in terms of international collaborations, Chinese companies are gradually becoming a force to be reckoned with. Whether through technology import or product export, Chinese pharmaceutical firms are actively exploring partnership models with international counterparts to accelerate their development. This is particularly evident in the antibody-drug conjugate (ADC) field, where Chinese companies have performed exceptionally well. A prime example is the collaboration between CSPC Pharmaceutical and Radiance Biopharma. Such cross-border partnerships not only enhance product market competitiveness but also lay a solid foundation for subsequent R&D efforts. How to get the latest progress on drug deals? If you would like to access the latest transaction event information, you can click on the 'Deal' module from the homepage of the Synapse database. Within the Deal module, you can search for global pharmaceutical transaction information using labels such as Drugs, Organization, Target, Drug Type, Deal Date.  Furthermore, you can obtain the original link to the transaction coverage by clicking on the "Deal Name." In the analysis view, you can see the most active assignors, assignees, popular targets, and other dimensions of analysis, as well as the distribution of research and development statuses at the time of the transaction, to help you better understand the search results. The Synapse database also supports the ability to view current transactions from the dimension of "drugs" (by selecting "drugs" from the "Adjust Dimension" dropdown menu above). Targeting transactions involving renowned pharmaceutical companies that are of interest to the industry, such as Merck, Roche, etc., Synapse has identified a group of "leading companies" through drugs that have achieved global sales exceeding 1 billion US dollars in 2022. Transactions involving drugs from these leading companies can be filtered by clicking on the "Leading Company" tag on the left-hand side. In addition to the drug transaction module, you can also view related transaction history on the drug detail page and the institution detail page. Click on the image below to explore new pharmaceutical funding transactions! 

As global healthcare continues to demand innovative therapies, February 2025 has emerged as a critical period witnessing the robust growth of the biopharmaceutical sector. This month has seen significant capital inflows supporting preclinical-stage research and multiple high-impact collaborations and licensing deals. For example, CSPC Pharmaceutical, through its subsidiary Megalith Biopharmaceutical, transferred the overseas rights of its ROR1-targeting antibody-drug conjugate (ADC), SYS6005, to Radiance Biopharma in a transaction valued at up to $1.24 billion. 1. Chiome Bioscience Partners with OmniAb for Efficient Bispecific Antibody Screening Chiome Bioscience has announced a collaborative research agreement with OmniAb, a company headquartered in Emeryville, California, to explore the synergistic effects of their technologies in bispecific antibody generation. This collaboration will integrate Chiome’s proprietary ADLib® system-based cell surface display technology with OmniAb’s OmniClic® transgenic chicken platform, which is designed to discover candidate monoclonal antibody arms. The partnership aims to establish a high-throughput screening system for bispecific antibodies, facilitating rapid evaluation of various combinations and providing strong technological support for future drug discovery. As part of this collaboration, Chiome plans to apply its new technology to its upcoming Integrated Drug Discovery (IDD) business, which focuses on antibody development platforms. By combining these two advanced technologies, Chiome seeks to enhance its profitability and provide more efficient solutions to its partners. Although the financial impact of this agreement on Chiome’s fiscal results for the year ending December 31, 2025, is expected to be minimal, it marks a significant step toward next-generation antibody drug discovery. Bispecific antibodies, an emerging antibody format designed based on novel mechanisms of action, have rapidly evolved in recent years, becoming a core component of next-generation antibody drug discovery. These antibodies can flexibly bind two different antigens, either targeting two distinct epitopes or identifying the most suitable monoclonal antibody pairs, which is critical for effective screening. Through this collaboration, Chiome and OmniAb aim to achieve breakthrough advancements in this field. OmniAb is renowned for licensing its cutting-edge discovery research technologies to pharmaceutical companies, biotech firms, and academic institutions to advance next-generation therapeutics. The OmniClic® technology, which features a common light chain, is specifically designed to facilitate bispecific antibody generation, significantly simplifying the design of complex antibody structures. Chiome's collaboration with OmniAb is based on the potential of OmniClic® to accelerate antibody drug development. Both parties aspire to drive innovation and development in this sector through their combined expertise. For Chiome’s IDD business, this research outcome will be a key driver of growth. The IDD business serves the diverse R&D needs of partner companies—ranging from pharmaceutical firms leveraging knowledge, experience, and technology—with the goal of achieving milestone-based revenue through collaborative antibody drug discovery. By integrating OmniAb’s technology, Chiome can not only enhance its own technical capabilities but also better serve its global partners, contributing to addressing unmet medical needs. 2. Magnet Biomedicine and Eli Lilly Join Forces to Pioneer Molecular Glue Therapy for Cancer Magnet Biomedicine, a biopharmaceutical company specializing in the discovery of molecular glues through rational screening and design, has announced a significant collaboration and licensing agreement with Eli Lilly and Company. The partnership aims to jointly discover, develop, and commercialize molecular glue therapies in the field of oncology. Leveraging Magnet’s TrueGlue™ discovery platform, the collaboration seeks to identify molecular glues that induce protein proximity and cooperativity, enabling novel mechanisms of action to tackle previously undruggable targets across various diseases and address unmet medical needs. Under the terms of the agreement, Magnet will receive up to $40 million in upfront, near-term payments, and equity investments. Additionally, Magnet is eligible for over $1.25 billion in milestone payments related to development, regulatory, and commercialization achievements, along with tiered royalties based on global net sales. This agreement not only validates Magnet’s technology but also reflects Lilly’s confidence in the future potential of this field. Through this collaboration, Magnet will further advance its innovative platform, while Lilly can leverage cutting-edge technology to provide more effective treatment options for patients. Molecular glues are small-molecule compounds that can alter the surface properties of target proteins, facilitating or inducing interactions with other proteins to achieve specific biological functions, such as protein degradation, pathway inhibition, or activation. Magnet’s TrueGlue™ platform emphasizes rational design over traditional serendipitous discovery methods, offering a more precise approach to identifying therapeutically promising molecular glues. In oncology, the application of molecular glues is particularly significant, as they can target disease-driving proteins that conventional drugs cannot effectively address, opening new avenues for cancer treatment. Lilly’s involvement extends beyond financial investment—it brings extensive technical expertise and experience to the partnership. As a leader in small-molecule drug development, Lilly will contribute its knowledge and resources in drug development, which is crucial for accelerating the transition from laboratory discoveries to clinical applications. This collaboration also underscores the growing potential of molecular glue technology as a revolutionary therapeutic approach, particularly in addressing traditionally "undruggable" targets. The partnership between Magnet Biomedicine and Eli Lilly represents a major advancement in the field of molecular glues, signaling the dawn of a new era in targeted therapies. With similar collaborations continuing to emerge, molecular glues have the potential to provide novel treatment options for various hard-to-treat diseases, including cancer. This innovation is not just a complement to existing therapies—it could fundamentally change the way certain diseases are treated, offering new hope for patients. Through such strategic collaborations, both companies are committed to driving scientific progress and improving global health outcomes. 3. Medigene and EpimAb Biotherapeutics Collaborate to Develop TCR-Guided T-Cell Engagers On February 27, 2025, Medigene AG and EpimAb Biotherapeutics announced a strategic collaboration to jointly research and develop off-the-shelf TCR-guided T-cell engagers (TCR-TCEs) for the treatment of immune-related diseases, including solid tumors. This collaboration leverages Medigene’s expertise in generating and characterizing TCRs with sensitivity, specificity, and safety (3S) alongside EpimAb’s proprietary CD3 antibody and T-FIT platform. Through this partnership, the two companies aim to develop highly targeted bispecific therapies that minimize off-target effects and improve patient outcomes. The bispecific therapy market presents significant opportunities in oncology, addressing critical unmet needs in both solid and hematologic malignancies. More than five million cancer patients globally face low five-year survival rates each year, underscoring the urgent demand for innovative treatments. Bispecific TCR-TCEs offer a promising solution by enabling the immune system to target and eliminate cancer cells with greater precision. The market for these therapies is projected to grow at a compound annual growth rate (CAGR) of 40.9% from 2023 to 2030, with an estimated market size exceeding $80 billion by 2030. 4. Unravel Biosciences and COMBINED Brain Join Forces to Advance Drug Discovery for Rare Neurological Diseases Unravel Biosciences and COMBINED Brain have announced a collaborative initiative aimed at identifying promising drug candidates for over 110 rare genetic neurological disorders represented by member patient advocacy groups. This collaboration represents one of the largest partnerships between the biopharmaceutical industry and patient communities, leveraging Unravel’s BioNAV™ drug discovery platform and COMBINED Brain’s extensive patient biosample repository. Through this partnership, the two organizations aim to rapidly identify therapies for clinical trials and provide timely treatment options for children with rare diseases. Unravel Biosciences’ BioNAV™ platform is an AI-powered target and drug discovery system that utilizes human health gene expression networks to identify small molecule modulators with potential therapeutic effects for complex diseases. Meanwhile, COMBINED Brain maintains a unique large-scale patient biosample collection, enabling the generation of RNA datasets to facilitate novel drug target discovery. This collaboration is not only focused on developing new drugs but also on repurposing existing approved medications to accelerate clinical translation and deliver patient benefits as quickly as possible. 5. HBM Alpha Therapeutics Enters Strategic Partnership to Advance Novel Endocrine Therapies HBM Alpha Therapeutics (HBMAT), an innovative biotechnology company incubated by HBM Holdings, has entered into a strategic collaboration and licensing agreement with a business partner to advance the development of therapies targeting corticotropin-releasing hormone (CRH). Under the agreement, the partner has secured exclusive development and commercialization rights for HAT001/HBM9013 outside Greater China. HAT001/HBM9013 is a potent and selective neutralizing antibody, and through this partnership, HBMAT is expected to receive up to $395 million in revenue, including upfront payments, milestone payments, and tiered royalties on future net sales. HAT001/HBM9013 is specifically designed to target CRH, reducing the adrenocorticotropic hormone (ACTH)-induced effects mediated by CRH. Preclinical studies have demonstrated significant efficacy, and the therapy is now advancing toward clinical development. This treatment holds potential for conditions such as congenital adrenal hyperplasia (CAH), a rare genetic disorder. Currently, CAH relies on treatment approaches developed over 70 years ago, with no significant updates in therapeutic options. The emergence of HAT001/HBM9013 could provide a breakthrough solution for patients. This partnership marks a significant milestone for HBMAT in its mission to develop innovative therapies for endocrine disorders and represents an important step in HBM Holdings’ global company incubation strategy. By collaborating with an experienced drug development partner, HAT001/HBM9013’s clinical progress is expected to accelerate, offering more effective treatment options for patients worldwide. Additionally, HBMAT holds warrant rights to acquire a minority equity stake in its partner, further strengthening its financial position and growth potential. HBMAT focuses on developing antibody therapies for rare genetic disorders such as congenital adrenal hyperplasia (CAH) and polycystic ovary syndrome (PCOS), addressing significant unmet medical needs. Beyond these indications, HAT001/HBM9013 may also be applicable to other disorders related to the hypothalamic-pituitary-adrenal (HPA) axis, highlighting its broad therapeutic potential and significant market opportunity. With the signing of this agreement, HBMAT will be able to concentrate resources and technological capabilities to accelerate the development of HAT001/HBM9013 and other promising therapies. This initiative represents not only a proactive response to current medical challenges but also a crucial step in future medical advancements. Through continuous technological innovation and strategic collaborations, HBMAT aims to establish itself as a leading biopharmaceutical company in the field of endocrine and related disorders, contributing to the improvement of human health. 6. IPA and RIBOPRO Collaborate to Advance mRNA-Driven Antibody Discovery, Ushering in a New Era of Immunotherapy ImmunoPrecise Antibodies Ltd. (IPA) and RIBOPRO have announced a strategic partnership aimed at revolutionizing the discovery and development of therapeutic antibodies. By integrating RIBOPRO's expertise in mRNA sequence optimization and lipid nanoparticle (LNP) delivery technology with IPA's advanced B-cell screening, single-cell analysis, and AI-driven discovery processes, the collaboration seeks to accelerate the development of novel therapeutics while enhancing antigen expression and immune response quality—critical steps in the antibody discovery process. Traditional immune-based antibody discovery platforms often face challenges in properly expressing complex antigens, which can hinder their ability to elicit effective immune responses. However, by leveraging RIBOPRO’s proprietary mRNA and LNP technologies, this collaboration enables precise and efficient antigen expression, potentially leading to stronger immune responses and a faster path to novel antibody therapeutics. This partnership introduces an innovative approach to overcoming long-standing challenges in antigen expression, opening new possibilities for precision medicine. IPA’s approach combines cutting-edge AI-driven analysis with highly specialized laboratory techniques to design and optimize antibodies with the highest clinical relevance. Incorporating mRNA immunization into IPA’s workflow is expected to further enhance the accuracy and efficiency of its antibody discovery pipeline. This collaboration exemplifies the convergence of modern biotechnology and artificial intelligence, playing a crucial role in accelerating drug development and improving success rates. 7. WuXi XDC and LigaChem Biosciences Strengthen Partnership to Accelerate ADC Therapeutic Innovations On February 25, 2025, WuXi XDC, a global leader in end-to-end CRDMO services for antibody-drug conjugates (ADCs) and other bioconjugates, announced the signing of an expanded Memorandum of Understanding (MOU) with LigaChem Biosciences. This agreement builds upon their existing collaboration since 2021 and aims to further accelerate the development of next-generation ADC therapies. Through this partnership, LigaChem will leverage WuXi XDC’s cutting-edge technologies and extensive expertise to significantly enhance the efficiency of its ADC development programs. Under the expanded MOU, WuXi XDC’s fully integrated ADC discovery platform will play a pivotal role in expediting LigaChem’s ADC research and development. By utilizing WuXi XDC’s advanced technologies and deep industry expertise, LigaChem can more effectively navigate all stages of ADC development, from discovery to clinical translation. Additionally, LigaChem will leverage WuXi XDC’s comprehensive ADC development and manufacturing platform to support multiple ADC projects, ensuring streamlined and efficient processes throughout the development cycle. Since initiating their partnership in 2021, WuXi XDC and LigaChem have made significant strides in advancing ADC and other bioconjugate innovations. This latest agreement further solidifies their shared commitment to driving the next wave of ADC breakthroughs, with the goal of delivering meaningful benefits to patients worldwide. As their collaboration deepens, both companies remain focused on leveraging continuous technological advancements and service innovations to accelerate the development of novel therapeutic solutions and improve patient outcomes. 8. BridGene and Takeda Partner to Advance Small Molecule Drug Discovery in Immunology and Neurology On February 25, 2025, BridGene Biosciences announced a strategic collaboration and licensing agreement with Takeda, a global pharmaceutical leader. Under this agreement, BridGene will utilize its proprietary chemoproteomics platform, IMTAC™, to discover novel small-molecule drug candidates in the fields of immunology and neurology. This collaboration targets historically "undruggable" targets, signifying both the recognition of BridGene’s technological capabilities and the potential for groundbreaking medical advancements. Through this partnership, BridGene stands to receive up to approximately $770 million in total payments from Takeda, including an upfront payment and early milestone payments totaling $46 million. Furthermore, if all milestones are achieved, BridGene may receive additional clinical and commercial milestone payments, along with tiered royalties on future sales. This financial structure not only provides strong funding support for BridGene but also incentivizes continuous innovation throughout the research and development process. For Takeda, this collaboration grants exclusive rights to develop and commercialize any potential products emerging from the partnership. IMTAC™, BridGene’s core technology platform, employs a chemoproteomics approach to identify small-molecule ligands for "undruggable" targets in a live-cell environment. What sets this technology apart is its ability to screen across the entire proteome, enabling the discovery of new disease-relevant targets and mechanisms. In the fields of immunology and neurology, IMTAC™ offers a promising avenue for identifying novel therapeutic strategies, bringing hope to patients with complex diseases. The collaboration is expected to investigate multiple targets, with both parties working together from the initial discovery of small-molecule candidates to the development of early lead compounds. If successful, this initiative will significantly expand the range of druggable targets, particularly for key molecular markers previously deemed intractable. With the emergence of more innovative therapies, this partnership is poised to enhance patient outcomes and pave new directions for the pharmaceutical industry. 9.ReCerise and NCCS Collaborate to Advance Innovative Hepatocellular Carcinoma Research On February 21, 2025, ReCerise Therapeutics, a company dedicated to developing first-in-class therapies for cancer, announced a partnership with the National Cancer Centre Singapore (NCCS) to develop innovative treatments for hepatocellular carcinoma (HCC) through multi-omics data analysis. This collaboration specifically focuses on RCT1213, an investigational candidate currently under development for HCC treatment. Through this joint research, both parties aim to conduct a multi-layered study on the potential of RCT1213. The collaboration will take place under the PLANet Project (Precision Medicine in Liver Cancer in the Asia-Pacific Network), an initiative led by NCCS based on the concept of intra-tumor heterogeneity and the highly dynamic tumor microenvironment (TME) of liver cancer. This longitudinal study will conduct comprehensive multi-omics analyses on tumor and blood samples from HCC patients. The project will leverage the extensive multi-omics data collected under the PLANet Project and will be led by world-renowned HCC expert Professor Pierce Chow. Professor Chow is a Senior Consultant in the Department of Surgery and Surgical Oncology at Singapore General Hospital (SGH) and NCCS, and he also serves as the Principal Investigator of the PLANet Project. While the specific mechanism of action of RCT1213 has not been fully disclosed, it is hypothesized that the therapy may target specific liver cell proteins or pathways that have shown promise as potential treatment targets. Through its collaboration with NCCS, ReCerise aims to investigate the expression of these targets in real-world HCC patient populations and assess their impact on the liver microenvironment. This effort will not only provide deeper insights into the mechanism of action of RCT1213 but also lay the groundwork for future clinical trials. Hepatocellular carcinoma is a highly prevalent cancer with poor prognosis, primarily due to late-stage diagnosis and the limited efficacy of existing immunotherapy options. ReCerise was founded with the mission of exploring and developing novel therapeutic approaches to address this significant unmet medical need. With promising preclinical research and proof-of-concept studies on a specific liver protein, ReCerise now has the opportunity to expand its research through this collaboration, paving the way for potential future commercialization. Notably, this research and development initiative has received financial support from the South Korean government and is managed and supervised by the Korea Evaluation Institute of Industrial Technology (KEIT). This public sector support, in addition to private investment, plays a crucial role in accelerating new drug development. Yong-Bae Kim, CEO of ReCerise Therapeutics, expressed excitement about collaborating with NCCS to advance the development of innovative liver cancer treatments. As more data is gathered and technological advancements continue, ReCerise is optimistic about bringing more effective treatment options to HCC patients. 10.GeneCradle Technology and Buyang Gene Technology Join Forces to Pioneer a New Era in Duchenne Muscular Dystrophy Gene Therapy On February 19, 2025, GeneCradle Technology and Buyang Gene Technology officially signed a strategic cooperation agreement to jointly develop next-generation gene therapies for Duchenne muscular dystrophy (DMD). This collaboration aims to address the urgent clinical needs of DMD patients and bring new hope for treatment. DMD is a severe genetic disorder for which no curative therapies currently exist, and available treatments only provide partial symptom relief. Since 2021, GeneCradle Technology has focused on developing gene therapy drugs for DMD, with a core emphasis on optimizing and engineering the Dystrophin protein and its regulatory elements. The company has innovatively designed Smart-Dystrophin, which, compared to conventional mini-Dystrophin or micro-Dystrophin, exhibits superior biological activity in various DMD animal models, potentially improving disease progression. Meanwhile, Buyang Gene Technology has developed a series of novel AAV capsids through its proprietary DynEvoLib® platform. These capsids offer enhanced muscle-targeting capabilities and higher transgene expression efficiency while reducing immunogenicity and improving safety. This partnership combines GeneCradle Technology's extensive expertise in AAV-based gene drug development with Buyang Gene Technology’s cutting-edge innovations in next-generation AAV capsid engineering. By leveraging their respective strengths, the collaboration is expected to enhance the efficacy and safety of DMD gene therapy while potentially reducing the required dosage, thereby minimizing potential side effects. Additionally, this cooperation will contribute to the advancement of China’s independent gene therapy research and development, bringing hope to rare disease patients both in China and globally. Duchenne muscular dystrophy (DMD) is an X-linked recessive genetic disorder caused by mutations in the dystrophin gene, primarily affecting males. The disease leads to progressive muscle fiber degradation and atrophy, ultimately resulting in the loss of ambulation and life-threatening cardiopulmonary complications. While corticosteroids such as prednisone can temporarily alleviate symptoms, their long-term use is associated with significant side effects, and they do not address the underlying disease mechanism. Consequently, the search for effective gene therapy solutions has become a key focus in DMD research. As GeneCradle Technology and Buyang Gene Technology deepen their collaboration, their efforts are expected to drive further progress in DMD gene therapy, offering patients safer and more effective treatment options. This partnership marks a significant milestone in technological innovation and has far-reaching implications for the field of gene therapy. With continued breakthroughs in this area, there is reason to believe that the quality of life for patients with DMD and other genetic disorders will improve substantially, providing valuable insights and technological advancements for future treatments. 11.Sunshine Guojian and Shenyang Sunshine Deepen Cooperation to Optimize Resource Allocation and Drive High-Quality Development On February 20, 2025, Sunshine Guojian announced that the company and its wholly-owned subsidiary, Dansheng Pharmaceutical, plan to sign a License Agreement with Shenyang Sunshine Pharmaceutical Co., Ltd., granting exclusive rights to Project 612 and Project 708 to Shenyang Sunshine. Under the agreement, Sunshine Guojian will receive an upfront payment of CNY 102 million, along with milestone-based payments and 15% of sales revenue as royalties. This transaction not only provides Sunshine Guojian with immediate cash inflow but also lays the foundation for future revenue growth. Project 612 is a novel anti-HER2 humanized monoclonal antibody, while Project 708 is a bispecific antibody targeting PD-1/TGF-β. Both drugs are currently in the preclinical stage, but research suggests they exhibit synergistic effects when used in combination, demonstrating significant anti-tumor efficacy. Through this collaboration, Shenyang Sunshine has acquired full rights for these projects in Mainland China, covering R&D, manufacturing, and commercialization, which will further accelerate the development of these innovative therapies. It is worth noting that Shenyang Sunshine and Sunshine Guojian are both subsidiaries of 3SBio, with Shenyang Sunshine directly holding 6.42% of Sunshine Guojian’s shares, making this a related-party transaction. Since Sunshine Guojian’s strategic shift to focus on the autoimmune disease field, Shenyang Sunshine has repeatedly acquired its non-core pipeline assets. Notable examples include large-scale transfers in April 2023 and June 2024, with total transaction amounts reaching several hundred million yuan. This model has enabled Sunshine Guojian to realign its business strategy while providing Shenyang Sunshine with new growth opportunities. Read the Rest of the Series Highlights of Financing and Strategic Collaborations in the Preclinical Biopharmaceutical Sector: February 2025(2) How to get the latest progress on drug deals? If you would like to access the latest transaction event information, you can click on the 'Deal' module from the homepage of the Synapse database. Within the Deal module, you can search for global pharmaceutical transaction information using labels such as Drugs, Organization, Target, Drug Type, Deal Date.  Furthermore, you can obtain the original link to the transaction coverage by clicking on the "Deal Name." In the analysis view, you can see the most active assignors, assignees, popular targets, and other dimensions of analysis, as well as the distribution of research and development statuses at the time of the transaction, to help you better understand the search results. The Synapse database also supports the ability to view current transactions from the dimension of "drugs" (by selecting "drugs" from the "Adjust Dimension" dropdown menu above). Targeting transactions involving renowned pharmaceutical companies that are of interest to the industry, such as Merck, Roche, etc., Synapse has identified a group of "leading companies" through drugs that have achieved global sales exceeding 1 billion US dollars in 2022. Transactions involving drugs from these leading companies can be filtered by clicking on the "Leading Company" tag on the left-hand side. In addition to the drug transaction module, you can also view related transaction history on the drug detail page and the institution detail page. Click on the image below to explore new pharmaceutical funding transactions!